iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
7.48
-0.37 (-4.71%)
May 14, 2025, 10:17 AM - Market open
iTeos Therapeutics Employees
iTeos Therapeutics had 173 employees as of December 31, 2024. The number of employees increased by 16 or 10.19% compared to the previous year.
Employees
173
Change (1Y)
16
Growth (1Y)
10.19%
Revenue / Employee
$202,312
Profits / Employee
-$756,133
Market Cap
286.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ITOS News
- 1 day ago - iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 15 days ago - iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless - Seeking Alpha
- 5 months ago - iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
- 5 months ago - iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - GlobeNewsWire
- 6 months ago - iTeos to Participate in Upcoming Investor Conferences - GlobeNewsWire